Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods – 1 August 2022

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the quality, safety, and efficacy of therapeutic goods in Australia. This Act was introduced to address the need for comprehensive oversight of therapeutic goods to protect public health. The Therapeutic Goods Administration (TGA), as the delegate of the Secretary of the Department of Health and Aged Care, is responsible for enforcing the provisions of this Act. The policy objective of the Act is to ensure that therapeutic goods available in Australia meet the necessary standards to safeguard the health and safety of consumers. Recently, the TGA published details concerning the suspension of licences for certain manufacturers of therapeutic goods. The suspensions, which were at the request of the manufacturers themselves, are intended to address specific quality or compliance issues. These actions demonstrate the TGA's commitment to maintaining high standards within the therapeutic goods industry and protecting the public from potentially harmful products.

Scope and Application

The Therapeutic Goods Act 1989 applies to all entities and individuals involved in the manufacture, supply, and importation of therapeutic goods within Australia, as well as to those entities and individuals conducting clinical trials with these goods. The scope of the Act encompasses the regulation of therapeutic goods such as medicines, medical devices, blood, and tissues, ensuring their quality, safety, and efficacy. The Act applies nationally across the Commonwealth of Australia, and its provisions are enforced by the Therapeutic Goods Administration (TGA), a department of the Australian Government. Certain classes of therapeutic goods may be exempt from some licensing requirements under the Act, such as over-the-counter medicines and low-risk medical devices. The application of the Act can also be extended or restricted through subordinate legislation, such as regulations and codes, which provide detailed guidance on specific aspects of the therapeutic goods industry. The Therapeutic Goods Act 1989 includes provisions for the suspension of manufacturing licences, as demonstrated by the recent notice published by the TGA. This notice informs the public of the suspension of licences held by Veolia Environmental Services (Australia) Pty Ltd, Royal Adelaide Hospital Radiopharmacy, and Global Medical Solutions Australia Pty Limited. These suspensions are at the request of the manufacturers themselves and are effective for specified periods, reflecting the TGA's commitment to maintaining high standards of quality and safety in the manufacture of therapeutic goods. The notice also serves to highlight the TGA's regulatory oversight and enforcement capabilities, ensuring compliance with the provisions of the Act across the therapeutic goods industry.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") governs the regulation of therapeutic goods in Australia, including the licensing of manufacturers. Section 41(1)(d) of the Act allows the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration to suspend a licence to manufacture therapeutic goods. This legislative power is exercised to ensure the safety and quality of therapeutic goods supplied in Australia. In this context, Katherine Clark, acting as the Delegate of the Secretary, has published the suspension of licences for certain manufacturers as required by Section 41 of the Act. The Act imposes specific obligations on the manufacturers of therapeutic goods, including compliance with licensing requirements, quality standards, and safety regulations. These obligations are crucial to ensure that therapeutic goods are manufactured to a standard that protects public health. The manufacturers whose licences have been suspended are required to cease operations related to the manufacture of therapeutic goods for the specified duration of the suspension. The publication of the suspension details serves to inform the public and relevant stakeholders of these changes, ensuring transparency and accountability in the therapeutic goods market. Failure to comply with the requirements of the Act, including the suspension of a licence, can lead to various consequences. While the Act itself does not specify offences, penalties, or civil/criminal consequences for breach of the suspension notice, breaches of other sections of the Act may result in significant penalties. For instance, unauthorised manufacturing activities can result in civil penalties up to $222,222 for a corporation and criminal penalties up to $1,111,110 for an individual, along with imprisonment terms. The severity of penalties underscores the importance of adhering to the provisions of the Act to maintain the integrity and safety of the therapeutic goods market in Australia.